| 000 | 01780 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517034340.0 | ||
| 264 | 0 | _c20160520 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1873-4294 | ||
| 024 | 7 |
_a10.2174/1568026615666150605115902 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarkoutsa, Eleni | |
| 245 | 0 | 0 |
_aComparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity. _h[electronic resource] |
| 260 |
_bCurrent topics in medicinal chemistry _c2015 |
||
| 300 |
_a2267-76 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aAmyloid _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aAmyloid beta-Peptides _ximmunology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xchemistry |
| 650 | 0 | 4 |
_aCell Line, Tumor _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCurcumin _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLigands |
| 650 | 0 | 4 |
_aLiposomes _xadministration & dosage |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNanoparticles _xadministration & dosage |
| 650 | 0 | 4 |
_aToxicity Tests _xmethods |
| 700 | 1 | _aMourtas, Spyridon | |
| 700 | 1 | _aBereczki, Erika | |
| 700 | 1 | _aZona, Cristiano | |
| 700 | 1 | _aLa Ferla, Barbara | |
| 700 | 1 | _aNicotra, Fransesco | |
| 700 | 1 | _aFlores, Orfeu | |
| 700 | 1 | _aPei, Jin-Jing | |
| 700 | 1 | _aAntimisiaris, Sophia G | |
| 773 | 0 |
_tCurrent topics in medicinal chemistry _gvol. 15 _gno. 22 _gp. 2267-76 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1568026615666150605115902 _zAvailable from publisher's website |
| 999 |
_c24952142 _d24952142 |
||